


EDELWEISS: ENDOMETRIOSIS PAIN CLINICAL RESEARCH STUDY



The Edelweiss study is assessing the safety and effectiveness of an investigational drug alone and in combination with hormonal add-back therapy compared to placebo in women with moderate to severe pain associated with endometriosis.

What drug is being tested?

Linzagolix, the investigational study drug, is:

- Designed to reduce the production of certain hormones
- Not currently approved by health authorities for treatment of moderate to severe pain associated with endometriosis

Will I receive the drug being tested?

You will be assigned by chance to take one of the following study treatments for 6 months:

- Linzagolix + placebo
- Linzagolix + hormonal add-back therapy
- Placebo + placebo

You will have an equal chance of being assigned each of these options.

What is hormonal add-back therapy?

Add-back therapy may lessen side effects of hormone reduction. It is often used for menopause symptom relief.

What is the placebo?

The placebo looks like linzagolix or add-back therapy but contains no active ingredients. Placebos are used to help evaluate an investigational drug by comparing the effects seen in study participants who take the investigational drug versus those who take placebo.

Can I continue taking pain medications?

The study doctor will prescribe or provide analgesics (pain medications) that you will be permitted to take during the study.

Will I be paid for participating?

You will receive all study medications and study-related tests and procedures at no cost. You will also receive a monthly stipend for each visit you complete, to reimburse you for your time and travel.

Who can participate in this study?

You may qualify to participate if you:

- Are 18 to 49 years old
- Have had a surgically confirmed diagnosis of endometriosis within the last 10 years
- Have endometriosis-associated pain during your period and at other times during your menstrual cycle
- Are not pregnant, breastfeeding, or planning to become pregnant
- Meet additional requirements as determined by a screening process

How long will I be in the study?

If you complete the study, your participation will last approximately 15 months:

- Screening period (up to 3 months)
- Study treatment period (6 months)
- Follow-up period (6 months)

What will happen if I join the study?

During the Edelweiss study, you will:

- Attend monthly study visits for health assessments during the study treatment and follow-up periods
- Take your study treatment once a day for 6 months
- Answer questions in an electronic diary

Can I continue study treatment afterwards?

If you complete the 6-month study treatment period, you may have the opportunity to enter a separate extension study in which you will receive active study treatment.

Can I leave the study after I start?

You can stop taking part in this study at any time. If you choose not to take part or you agree to take part but then withdraw, medical care you receive outside the study will not be affected. The study doctor will discuss other treatment options with you.

[EdelweissEndometriosis.com](https://www.EdelweissEndometriosis.com)